Patient preference doesn't affect chemo in advanced CRC

September 21, 2012
Patient preference doesn't affect chemo in advanced CRC
For patients with metastatic colorectal cancer, most patients are treated with chemotherapy, even if they express negative or marginal preferences, according to a study published online Sept. 12 in Cancer.

(HealthDay)—For patients with metastatic colorectal cancer (mCRC), most patients are treated with chemotherapy, even if they express negative or marginal preferences, according to a study published online Sept. 12 in Cancer.

S. Yousuf Zafar, M.D., M.H.S., of the Duke Cancer Institute in Durham, N.C., and colleagues conducted a involving 702 patients with mCRC to determine how patient preferences guide the course of palliative .

Overall, 91 percent of patients were treated by a medical oncologist, and 82 percent of these received chemotherapy. The researchers found that patients aged 65 to 75 years or 75 years and older were less likely to visit an oncologist, as were those who were too unwell to complete their own survey. Patients who were 75 years or older with moderate or severe comorbidities or patients who were too unwell to complete their own survey were less likely to receive chemotherapy. Patients tended to receive chemotherapy even when they felt that treatment would not extend their lives (90 percent) or help them with their cancer-related problems (89 percent), and even when they stated a preference to focus on comfort rather than extending their life (90 percent).

"In summary, in the palliative setting were not always congruent with stated preferences and beliefs regarding chemotherapy," the authors write. "The vast majority of patients who expressed negative or marginal preferences or beliefs regarding chemotherapy still received chemotherapy. Patient preferences and beliefs were not associated with the intensity or number of chemotherapy regimens received."

Several authors disclosed financial ties to the .

Explore further: ASCO: Continuing avastin with 2nd-line chemo ups survival

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

ASCO: Continuing avastin with 2nd-line chemo ups survival

June 5, 2012
(HealthDay) -- Continuing use of bevacizumab (Avastin) in combination with second-line chemotherapy improves overall survival (OS) and progression-free survival (PFS) in patients with metastatic colorectal cancer (mCRC) who ...

Certain head and neck cancer patients benefit from second round of treatment

June 13, 2011
A new study has determined predictors that can better identify patients who will benefit from a potentially toxic second course of treatment, which offers a small but real chance of cure in select patients with head and neck ...

Chemotherapy is as effective before breast cancer surgery as after

September 8, 2011
Whether chemotherapy is given before or after breast-conserving therapy (BCT) does not have an impact on long-term local-regional outcomes, suggesting treatment success is due more to biologic factors than chemotherapy timing, ...

Breast cancer survivors struggle with cognitive problems several years after treatment

December 12, 2011
A new analysis has found that breast cancer survivors may experience problems with certain mental abilities several years after treatment, regardless of whether they were treated with chemotherapy plus radiation or radiation ...

Nelarabine plus chemo viable in children with T-cell ALL

June 29, 2012
(HealthDay) -- Treatment of children with newly-diagnosed T-cell acute lymphoblastic leukemia (T-ALL) with nelarabine, in addition to an intensive Berlin-Frankfurt-Münster (BFM) 86-based chemotherapy regimen, is feasible ...

Recommended for you

More evidence of link between severe gum disease and cancer risk

January 16, 2018
Data collected during a long-term health study provides additional evidence for a link between increased risk of cancer in individuals with advanced gum disease, according to a new collaborative study led by epidemiologists ...

Researchers develop a remote-controlled cancer immunotherapy system

January 15, 2018
A team of researchers has developed an ultrasound-based system that can non-invasively and remotely control genetic processes in live immune T cells so that they recognize and kill cancer cells.

Pancreatic tumors may require a one-two-three punch

January 15, 2018
One of the many difficult things about pancreatic cancer is that tumors are resistant to most treatments because of their unique density and cell composition. However, in a new Wilmot Cancer Institute study, scientists discovered ...

New immunotherapy approach boosts body's ability to destroy cancer cells

January 12, 2018
Few cancer treatments are generating more excitement these days than immunotherapy—drugs based on the principle that the immune system can be harnessed to detect and kill cancer cells, much in the same way that it goes ...

Cancer's gene-determined 'immune landscape' dictates progression of prostate tumors

January 12, 2018
The field of immunotherapy - the harnessing of patients' own immune systems to fend off cancer - is revolutionizing cancer treatment today. However, clinical trials often show marked improvements in only small subsets of ...

FDA approves first drug for tumors tied to breast cancer genes

January 12, 2018
(HealthDay)—The U.S. Food and Drug Administration on Friday approved the first drug aimed at treating metastatic breast cancers linked to the BRCA gene mutation.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.